Windlas Biotech vs Peers
- Market cap
- ₹2,008 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹685.08 – ₹1,284.53
Windlas Biotech ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Windlas Biotech. Its P/E of 22.5 compares with a peer median of 22.5.
Windlas Biotech vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Windlas Biotech | 951.50 | -6.90% | 2,008 | 22.5 | 2.85 | 14.5% | +18.5% |
| Windlas Biotech | 951.50 | -6.90% | 2,008 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Windlas Biotech peer comparison — frequently asked questions
Who are Windlas Biotech's competitors?
Windlas Biotech's listed peers in Drug Manufacturers - Specialty & Generic include Windlas Biotech, ranked here by market capitalisation.
How does Windlas Biotech's P/E compare with its peers?
Windlas Biotech trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Windlas Biotech's peers?
By market capitalisation, the largest company in the group is Windlas Biotech at ₹2,008 crore, against ₹2,008 crore for Windlas Biotech.
Same Data For Peers
Trade Windlas Biotech With ATS
Track WINDLAS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.